{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=39",
    "query": {
      "intervention": "normal saline solution placebo",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1624,
    "total_pages": 163,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T22:39:00.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05977400",
      "title": "NICU Antibiotics and Outcomes (NANO) Follow-up Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Premature Birth",
        "Antibiotics",
        "Neurodevelopment"
      ],
      "interventions": [
        {
          "name": "Ampicillin",
          "type": "DRUG"
        },
        {
          "name": "Gentamicin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sharp HealthCare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Weeks",
        "maximum_age": "30 Weeks",
        "sex": "ALL",
        "summary": "23 Weeks to 30 Weeks"
      },
      "enrollment_count": 802,
      "start_date": "2024-04",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 14,
      "location_summary": "San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05977400"
    },
    {
      "nct_id": "NCT05684692",
      "title": "Screening Trial for Pain Relief in Schwannomatosis (STARFISH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schwannomatosis",
        "Schwannomas",
        "Pain, Chronic"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Erenumab-Aooe",
          "type": "DRUG"
        },
        {
          "name": "Siltuximab Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Erenumab-Aooe Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-08-31",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05684692"
    },
    {
      "nct_id": "NCT02975999",
      "title": "Use of Vasopressin Following the Fontan Operation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pleural Effusion",
        "Single-ventricle"
      ],
      "interventions": [
        {
          "name": "Vasopressin",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "18 Months to 7 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-12",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Oak Lawn, Illinois",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02975999"
    },
    {
      "nct_id": "NCT05677893",
      "title": "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)"
      ],
      "interventions": [
        {
          "name": "MBS-COV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Oneness Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-11-07",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05677893"
    },
    {
      "nct_id": "NCT04784767",
      "title": "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride, USP, for injection (0.9% NaCl)",
          "type": "DRUG"
        },
        {
          "name": "50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-05",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784767"
    },
    {
      "nct_id": "NCT05661409",
      "title": "Sugammadex as Rescue Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2023-07-21",
      "completion_date": "2024-08-02",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05661409"
    },
    {
      "nct_id": "NCT02230917",
      "title": "A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Silbermann",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230917"
    },
    {
      "nct_id": "NCT02703090",
      "title": "Near Infrared Spectroscopy Cortical Response to Noxious and Auditory Stimuli in Subjects Under General Anesthesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anesthesia",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Remifentanil",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-10",
      "completion_date": "2020-03-10",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02703090"
    },
    {
      "nct_id": "NCT02026297",
      "title": "Tranexamic Acid and Thromboelastography During Cesarean Delivery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postpartum Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo; Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2014-07",
      "completion_date": "2020-02-21",
      "has_results": true,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02026297"
    },
    {
      "nct_id": "NCT05350774",
      "title": "Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Inflammation",
        "Neuroinflammation",
        "Microvascular Thrombosis"
      ],
      "interventions": [
        {
          "name": "IV normal saline",
          "type": "DRUG"
        },
        {
          "name": "IV immunoglobulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 45,
      "start_date": "2023-07-10",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-16T22:39:00.784Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05350774"
    }
  ]
}